coronary atherosclerotic heart disease
Conditions
Interventions
berberine group:The routine therapy with berberine 0.4g po t.i.d
Sponsors
The First Affiliated Hospital of Henan University of CM
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Male or female aged 15 to 70 years old; 2. Consistent with NSTE-ACS diagnosis; 3. Patients who were confirmed to be suitable and successfully treated with PCI stents; 4. Patients agree with this clinical trail and sign the medical informed consent.
Exclusion criteria
Exclusion criteria: (1) STEMI,stable angina, aortic dissection, myocarditis, pericarditis, myocardiopathy, valvular disease; (2) Patients with pulmonary embolism, acute febrile and other inflammatory diseases and active infections, severe damage of liver or kidney (AST or ALT>3 times normal upper limit, TBIL>2 times normal upper limit), malignant tumors and hemorrhagic diseases; (3) Patients with Hemodynamic instability or serious complications after PCI; (4) Allergic to the experimental drug; (5) Patients in another clinical trial and take their research drugs; (6) Life expectancy was shorter than the duration of the study; (7) pregnant women; (8) favism; (9) Patients with any other conditions considered cannot be recruited.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| coronary artery stenosis;adverse cardiovascular and cerebrovascular events within 12 months after PCI; | — |
Secondary
| Measure | Time frame |
|---|---|
| fasting blood glucose;Glycosylated hemoglobin;lipid metabolism;CRP;uric acid;homocysteine;blood pressure;Platelet inhibition ratio;PCSK9;PTX-3; | — |
Countries
China
Contacts
Public ContactHuaimin Guan
The First Affiliated Hospital of Henan University of CM
Outcome results
None listed